TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED vs WILMAR INTERNATIONAL LIMITED
Side-by-side financial comparison. FY2025 data.
| Metric | T14 | F34 | Winner |
|---|---|---|---|
| Revenue | 4,917M | 245,126M | F34 |
| Net Profit | 2,131M | 3,153M | F34 |
| EPS (cents) | 277 | 58 | T14 |
| Total Assets | 11,690M | 228,720M | F34 |
| Total Equity | 7,100M | 96,432M | F34 |
| Net Margin | 43.3% | 1.3% | T14 |
| ROE | 30.0% | 3.3% | T14 |
Revenue Comparison
Net Profit Comparison
About This Comparison
This page compares TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED (T14) and WILMAR INTERNATIONAL LIMITED (F34), both listed on the Singapore Exchange (SGX). In FY2025, T14 reported revenue of SGD 4,917M compared to F34's SGD 245,126M. T14 earned a net profit of SGD 2,131M while F34 earned SGD 3,153M. Data is extracted directly from SGX company announcements and updated daily.